[1]毛明强,邹 婧,郑 静,等.一种磷酸二酯酶抑制剂异去甲蟛蜞菊内酯对HT-22细胞的保护作用[J].常州大学学报(自然科学版),2019,31(05):87-92.[doi:10.3969/j.issn.2095-0411.2019.05.013]
　MAO Mingqiang,ZOU Jing,ZHENG Jing,et al.Protective Effect of Phosphodiesterase Inhibitor DWEL on HT-22 Cells Damage[J].Journal of Changzhou University(Natural Science Edition),2019,31(05):87-92.[doi:10.3969/j.issn.2095-0411.2019.05.013]
点击复制

一种磷酸二酯酶抑制剂异去甲蟛蜞菊内酯对HT-22细胞的保护作用()
分享到：

常州大学学报(自然科学版)[ISSN:2095-0411/CN:32-1822/N]

卷:
第31卷
期数:
2019年05期
页码:
87-92
栏目:
生物医学工程
出版日期:
2019-09-28

文章信息/Info

Title:
Protective Effect of Phosphodiesterase Inhibitor DWEL on HT-22 Cells Damage
文章编号:
2095-0411(2019)05-0087-06
作者:
毛明强; 邹 婧; 郑 静; 丁淑敏; 吴香莹; 周冬雷; 孙毅立
(常州大学 制药与生命科学学院,江苏 常州 213164)
Author(s):
MAO Mingqiang;  ZOU Jing;  ZHENG Jing;  DING Shumin;  WU Xiangying;  ZHOU Donglei;  SUN Yili
(School of Pharmaceutical Engineering & Life Science,Changzhou University,Changzhou 213164,China)
关键词:
磷酸二酯酶;  异去甲蟛蜞菊内脂;  抑制作用;  神经细胞
Keywords:
PDEs;  Demethylwedelolactone;  inhibition;  nerve cells
分类号:
R 285
DOI:
10.3969/j.issn.2095-0411.2019.05.013
文献标志码:
A
摘要:
磷酸二酯酶(PDEs)是催化水解细胞内第二信使cAMP和cGMP的唯一途径,而磷酸二酯酶抑制剂可通过改变cAMP和cGMP的浓度从而调节学习与认知功能障碍等多种生理过程。异去甲蟛蜞菊内酯(Demethylwedelolactone,DWEL)是墨旱莲的主要成分之一。实验采用Alpha试剂盒确认DWEL对PDE2A有一定的抑制作用,其 IC50为9.17 μmol·L-1; 而对PDE4D和PDE10A无明显抑制作用,说明DWEL对磷酸二酯酶的抑制具有一定选择性。可的松诱导HT-22细胞模型发现,不同浓度的DWEL给药后细胞活力不断提高,浓度到达20 μmol·L-1时,细胞活力为76.98%(P<0.05),结果表明DWEL对神经细胞有一定保护作用。
Abstract:
Phosphodiesterase PDEs are the only pathways that catalyze the hydrolysis of second messenger cAMP and cGMP in cells. Phosphodiesterase(PDE)inhibitors can regulate learning and cognitive dysfunction(AD)by altering the concentrations of cAMP and cGMP. Demethylwedelolactone(DWEL)is one of the main components of Eclipta prostrata L. Alpha kit test confirmed the inhibition effect of Demethylwedelolactone on PDE2A with IC50 value 9.17 μmol·L-1. However, no obvious inhibition effect was found on PDE4D and PDE10A which indicate Demethylwedelolactone can inhibit PDE2A selectively. HT-22 cell model induced by cortisone showed that Demethylwedelolactone could increase the survival rate of HT-22 cell cells. When the concentration reached 20 μmol·L-1, the cell viability was 76.98%(P<0.05). These results suggested that DWEL could protect HT-22 cell indured by cortisone.

参考文献/References:

[1]黄浩.以磷酸二酯酶为主要靶点的阿魏酸抗阿尔兹海默病作用机制研究[D]. 北京:北京工业大学,2016.
[2]万素馨,方伟. 阿尔茨海默病的治疗药物作用机制研究进展[J]. 现代药物与临床,2018,33(12):3406-3410.
[3]ADLIMOGHADDAM A, NEUENDORF M,ROY B,et a1.A review of clinical treatment considerations of donepezil in severe Alzheimer’s disease[J].CNS Neurosci Ther, 2018,24(10):876-888.
[4]LOVESTONE S,BOADA M,DUBOIS B,et a1.A phase II trial of tideglusib in Alzheimer’s disease[J].Alzheimers Dis,2015,45(1):75-88.
[5]MATHURAM T L,REECE L M,CHERIAN K M.GSK-3inhibitors:a double edged sword-an updam on tideglusib[J].Drug Res(Stuttg),2018,68(8):436-443.
[6]张莉,杜冠华. 磷酸二酯7:一个新的抗炎免疫药物靶点研究进展[J]. 中国药理学通报,2009,25(1):1-4.
[7]XU Y, ZHANG H T,ODONNELL J M. Phosphodiesterases in the central nervous system:implications in mood and cognitive disorders[J]. Handb Exp Pharmacol,2011(204):447-485.
[8]HECKMAN P R,BLOKLAND A,RAMAEKERS J,et al. PDE and cognitive processing:beyond the memory domain[J]. Neurobiol Learn Mem,2015(119):108-122.
[9]BENDER A T, BEAVO J A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use[J]. Pharmacol Rev,2006,58(3):488-520.
[10]JUNG W Y, KIM H, PARK H J,et al. The ethanolic extract of the Eclipat prostrata L. ameliorates the cognitive impairment in mice induced by scopolamine[J]. Journal of Ethnopharmacology, 2016,190:165-173.
[11]GINTER E,SIMKO V,WEINREBOVA D,et al. Novel potential for the management of Alzheimer disease[J]. Bratisl Lek Listy,2015,116(10):580-581.
[12]ROULEAU N,TUROTTE S,MONDOU M H,et al. Development of a versatile platform for nuclear receptor screening using AlphaScreen[J]. J Biomol Screen,2003,8:191-197.
[13]BERNABEU R,SCHMITZ P, FAILLACE M P,et al. Hippocampal cGMP and cAMP are differentially involved in memory processing of inhibitory avoidance learning[J]. Neuroreport,1996,7:585-588.
[14]MORITA H,MURATA T,SHIMIZU K,et al. Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells[J]. Oncol REP,2013,29(4):1275-1284.
[15]RENEERKENS O A,RUTTEN K,BOLLEN E,et al. Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801[J]. Behav Brain Res,2013,236(1):16-22.
[16]LUGNIER C.Cyclic nucleotide phosphodiesterase(PDE)super family:a new target for the development of specific therapeuticgents[J].Pharmacol Ther,2006,109(3):366-398.
[17]GOMEZ L, MASSARI M E, VICKERS T, et al. Design and synthesis of novel and selective phosphodiesterase 2(PDE2a)inhibitors for the treatment of memory disorders[J]. J Med Chem,2017,60(5):2037-2051.
[18]MENNITI F S, FARACI W S, SCHMIDT C J. Phosphodiesterases in the CNS: targets for drug development[J]. Nat Rev Drug Discovery,2006,5(8):660-670.
[19]LUEPTOW L M, ZHAN C G, O’DONNELL J M. Cyclic GMP-mediated memory enhancement in the object recognition test by inhibitors of phosphodiesterase-2 in mice[J]. Psychopharmacology,2016,233(3):447-456.
[20]BOESS F G, HENDRIX M, VANDERSTAAY F J, et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance[J]. Neuropharmacology,2004,47(7):1081-1092.

备注/Memo

备注/Memo:
收稿日期:2019-04-04。
基金项目:国家自然科学基金资助项目(81603336)。
作者简介:毛明强(1995—),男,江苏南京人,硕士生。 通信联系人:丁淑敏(1978—),E-mail:dsm@cczu.edu.cn
更新日期/Last Update: 2019-09-30